Antiviral treatment of cytomegalovirus infection: an update (Q43992958)

28 November 2017

0 references

Antiviral treatment of cytomegalovirus infection: an update (English)

1 reference

28 November 2017

0 references

cytomegaloviral disease

1 reference

Georg Härter

1

1 reference

28 November 2017

Detlef Michel

series ordinal

2

1 reference

28 November 2017

language of work or name

English

0 references

publication date

2 February 2012

1 reference

Expert Opinion on Pharmacotherapy

28 November 2017

published in

1 reference

28 November 2017

volume

13

1 reference

28 November 2017

issue

5

1 reference

28 November 2017

page(s)

623-627

1 reference

International consensus guidelines on the management of cytomegalovirus in solid organ transplantation

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658775

Drug-resistant cytomegalovirus in transplant recipients: a French cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658775

Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658775

Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658775

Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658775

Pyrosequencing allows the detection of emergent ganciclovir resistance mutations after HCMV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658775

Improved detection of mutated human cytomegalovirus UL97 by pyrosequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658775

Deep sequencing reveals highly complex dynamics of human cytomegalovirus genotypes in transplant patients over time

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658775

Mass spectrometry-based comparative sequencing to detect ganciclovir resistance in the UL97 gene of human cytomegalovirus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658775

Diversity of antiviral-resistant human cytomegalovirus in heart and lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658775

Cytomegalovirus quantification: where to next in optimising patient management?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658775

The biology of cytomegalovirus drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658775

Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658775

A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658775

Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658775

Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658775

Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658775

Utility of Leflunomide in the Treatment of Complex Cytomegalovirus Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658775

Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658775

Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658775

Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658775

In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658775

The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658775

Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658775

10.1517/14656566.2012.658775

21 January 2018

Identifiers

DOI

1 reference

28 November 2017

1 reference